Efficacy of Botulinum Toxin Type-A I in the Improvement of Mandibular Motion and Muscle Sensibility in Myofascial Pain TMD Subjects: A Randomized Controlled Trial

• Published in: Toxins Vol. 14; no. 7; p. 441
• Main Authors: De la Torre Canales, Giancarlo, Poluha, Rodrigo Lorenzi, Pinzón, Natalia Alvarez, Da Silva, Bruno Rodrigues, Almeida, Andre Mariz, Ernberg, Malin, Manso, Ana Cristina, Bonjardim, Leonardo Rigoldi, Rizzatti-Barbosa, Célia Marisa
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 29.06.2022; MDPI
• Subjects: Botulinum toxin; Botulinum toxin type A; Care and treatment; Causes of; Clinical medicine; Clinical trials; Diagnosis; Disability; Dosage and administration; Joints; Mandible; Mouth; Muscle pain; Muscles; myofascial pain; Pain; Patients; Prevention; Range of motion; Saline solutions; Statistical analysis; Temporalis muscle; temporomandibular disorders; Temporomandibular joint disorders; Toxins; Portugal
• ISSN: 2072-6651; 2072-6651
• DOI: 10.3390/toxins14070441

This study assessed the effects of botulinum toxin type A (BoNT-A) in mandibular range of motion and muscle tenderness to palpation in persistent myofascial pain (MFP) patients (ReBEC RBR-2d4vvv). Eighty consecutive female subjects with persistent MFP, were randomly divided into four groups (n = 20): three BoNT-A groups with different doses and a saline solution group (placebo control group). Treatments were injected bilaterally in the masseter and anterior temporalis muscle in a single session. Clinical measurements of mandibular movements included: pain-free opening, maximum unassisted and assisted opening, and right and left lateral excursions. Palpation tests were performed bilaterally in the masseter and temporalis muscle. Follow-up occurred 28 and 180 days after treatment. For the statistical analysis the Mann–Whitney U-test with Bonferroni correction was used for groups comparisons. Regardless of dose, all parameters of mandibular range of motion significantly improved after 180 days in all BoNT-A groups, compared with the control group. Palpation pain over the masseter and temporalis muscles were significantly reduced in all BoNT-A groups regardless of dose, compared with the control group, after 28 and 180 days of treatment. Independent of doses, BoNT-A improved mandibular range of motion and muscle tenderness to palpation in persistent MFP patients.